PRINT THIS PAGE

Reithinger leaves 3i for German Global Life Science Ventures

GLSV has announced that Dr. Holger Reithinger has joined their investment team as Principal, and will be operating out of their Munich office.

Dr. Reithinger comes to GLSV from the 3i Group where he was a Director at 3i Germany's healthcare practice. In this role, he specialized in early-stage to mid-stage healthcare investments across Europe.

He will provide management and guidance for GLSV's portfolio of life science companies and the firm said that Reithinger will play a key role in evaluating new investment opportunities for the fund.

Hans Küpper, a Partner at Global Life Science Ventures, commented: "It gives us great pleasure to welcome Dr. Reithinger to our investment team. His inside knowledge of the healthcare sector and broad network of contacts throughout Europe ideally complement our existing team of professionals."

Hanns-Peter Wiese, also a Partner at GLSV, added: "Holger, whom we have known personally since 1997, has a strong track record in the venture capital industry and has served on the boards of several early-stage life science companies, some of which were supported through our first fund. His proven experience will be extremely useful as we continue to build our investment portfolio and brand name as a leading European venture capital group dedicated to the life sciences."

Dr. Reithinger holds a PhD in Biochemistry from the University of Frankfurt / Max-Planck-Institute of Biophysics where he worked on protein design in the department of Nobel Laureate Professor Dr. Hartmut Michel.

Operating out of offices in Germany, Switzerland and the UK, GLSV has so far financed 30 biotechnology companies, five of which have completed an exit through IPOs or trade-sales.

Copyright © 2004 AltAssets